UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | C000000134 |
|---|---|
| Receipt number | R000000197 |
| Scientific Title | Phase II study of topotecan and cisplatin for elderly small-cell lung cancer |
| Date of disclosure of the study information | 2005/09/12 |
| Last modified on | 2016/09/15 19:22:37 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase II study of topotecan and cisplatin for elderly small-cell lung cancer
Acronym
Phase II study of topotecan and cisplatin for elderly small-cell lung cancer
Scientific Title
Phase II study of topotecan and cisplatin for elderly small-cell lung cancer
Scientific Title:Acronym
Phase II study of topotecan and cisplatin for elderly small-cell lung cancer
Region
| Japan |
Condition
Condition
Elderly small-cell lung cancer
Classification by specialty
| Pneumology | Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To evaluate efficacy and safety of the combination chemotherapy.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Explanatory
Developmental phase
Phase II
Assessment
Primary outcomes
Response rate
Key secondary outcomes
Adverse events, overall survival, 1-year survival rate
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Historical
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Combination chemotherapy of topotecan and cisplatin
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 76 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Histologically and/or cytologically proven SCLC
No prior surgery, chemotherapy, or radiotherapy
Age ≥76
ECOG performance status 0, 1 or 2
Measurable disease
adequate bone marrow, lung, hepatic, and renal function
Written informed consent
Key exclusion criteria
Active concomitant malignancy
Active interstitial pneumonia
Massive effusions
Unstable angina, recent myocardial infarction
Uncontrolled diabetes
Symptomatic brain metastasis
Severe active infection
Other severe complications
Inappropriate condition for this study judged by physicians.
Target sample size
55
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Mitsune Tanimoto |
Organization
Okayama University Hospital
Division name
Hematology, Oncology, Respiratory Medicine
Zip code
Address
2-5-1 Shikata-cho, Okayama 700-8558
TEL
086-235-7227
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Nagio Takigawa |
Organization
Okayama Lung Cancer Study Group Coordinating Office
Division name
Okayama University Hospital, Respiratory Medicine
Zip code
Address
2-5-1 Shikata-cho, Okayama 700-8558
TEL
086-235-7227
Homepage URL
ntakigaw@md.okayama-u.ac.jp
Sponsor or person
Institute
Okayama Lung Cancer Study Group
Institute
Department
Personal name
Funding Source
Organization
none
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2005 | Year | 09 | Month | 12 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
http://link.springer.com/article/10.1007%2Fs00280-016-3135-2
Number of participants that the trial has enrolled
Results
This regimen produced a favorable survival outcome (median: 22.2 months), despite moderate-to-severe toxicity profiles.
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2004 | Year | 11 | Month | 05 | Day |
Date of IRB
Anticipated trial start date
| 2004 | Year | 12 | Month | 01 | Day |
Last follow-up date
| 2011 | Year | 12 | Month | 01 | Day |
Date of closure to data entry
| 2016 | Year | 06 | Month | 01 | Day |
Date trial data considered complete
| 2016 | Year | 06 | Month | 01 | Day |
Date analysis concluded
| 2016 | Year | 08 | Month | 01 | Day |
Other
Other related information
Management information
Registered date
| 2005 | Year | 09 | Month | 08 | Day |
Last modified on
| 2016 | Year | 09 | Month | 15 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000197
